
Releases
Evotec Trims 2026 Outlook Amid Revenue Shortfall
Hamburg-based biotech firm Evotec SE has issued a stark revision to its 2026 financial forecast, citing disappointing performance in the first half of the year. Preliminary data reveals a significant gap between previous guidance and the company’s current trajectory, prompting an immediate recalibration of its full-year revenue and EBITDA targets.




.jpg)





















